Chief Medical Officer / Managing Director ITM Oncologics
Philip E Harris, BSc MB BCh PhD FRCP FRSB was appointed Chief Medical Officer of ITM Isotopen Technologien München AG in June 2018. He is responsible for providing clinical leadership to ITM's radiopharmaceutical development platform. With more than 16 years of leadership experience in industry, Philip has contributed greatly to the development of various theranostic radionuclide therapy platforms in Oncology. His previous industry positions include Director of Global Medical Affairs at Pharmacia, Senior Director of Clinical Development at Pfizer, and Vice President at Ipsen. Philip is a distinguished clinical endocrinologist and general physician, with a strong academic background. Prior to moving into industry, he held an academic consultant appointment at King’s College Hospital, London in internal medicine and adult endocrinology.
Philip holds a Bachelor of Medicine & Surgery and a PhD from the University of Wales (UK).